Welcome to our dedicated page for Gyre Therapeutics SEC filings (Ticker: GYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gyre Therapeutics, Inc. filings document a commercial-stage biopharmaceutical issuer with U.S. and China operations, revenue from Gyre Pharmaceuticals, and a pipeline centered on anti-fibrotic therapies and targeted protein degradation assets. Form 8-K reports cover operating results, business updates, CDE/NMPA regulatory disclosures for F351, and clinical-program updates for Hydronidone and pirfenidone.
Proxy and material-event filings describe governance matters, shareholder voting items, material agreements, capital-structure disclosures and the completed Cullgen acquisition, including preferred-stock and common-stock conversion mechanics. The record also includes Regulation FD disclosures addressing commercial products, research spending and pipeline development.
GYRE THERAPEUTICS, INC. Chief Operating Officer Weiguo Ye reported an exercise-and-sell sequence in company stock. On June 9 and 10, 2026, he sold a total of 20,918 shares of common stock in open-market transactions at reported prices of $6.14 and $6.21 per share, with actual sales executed across price ranges detailed in the footnotes.
On the same dates, he exercised stock options to acquire the same total of 20,918 shares of common stock at an exercise price of $0.75 per share. Following these transactions, he directly held 700,000 shares of common stock. The options exercised were reported as vested in full, and no remaining derivative positions are listed in this filing.
GYRE THERAPEUTICS, INC. reported a Form 4 showing that GC and Corporate Secretary Joshua Benjamin Bergmann received a grant of stock options to acquire 50,000 shares of common stock at an exercise price of $6.05 per share. These options expire on June 8, 2036. According to the vesting terms, 25% of the grant will vest on June 8, 2027, with the remainder vesting in equal monthly installments over the following three years, subject to continued service. After this grant, Bergmann holds 50,000 derivative securities directly, reflecting routine equity-based compensation rather than an open-market purchase or sale.
GYRE THERAPEUTICS, INC. reported that Chief Executive Officer Luo Ying received a grant of stock options covering 120,000 shares of common stock. The options have an exercise price of $6.05 per share and expire on June 8, 2036.
According to the grant terms, 25% of the options will vest on June 8, 2027, with the remaining options vesting in equal monthly installments over the following three years, subject to Luo Ying’s continued service. Following this award, the filing shows 120,000 derivative securities held directly.
GYRE Therapeutics Chief Operating Officer Ye Weiguo reported an exercise-and-sell sequence in company stock. On June 4, 2026 and June 5, 2026, he exercised stock options to acquire a total of 34,976 shares of common stock at an exercise price of $0.75 per share and then sold the same number of shares in open-market transactions.
The 19,575-share sale on June 4 occurred at a weighted average price of $6.13 per share in trades ranging from $6.05 to $6.30, while the 15,401-share sale on June 5 was at a weighted average price of $6.40 per share in trades ranging from $6.15 to $6.60. After these transactions, Weiguo directly holds 700,000 shares of GYRE common stock.
Gyre Therapeutics, Inc. furnished an updated corporate presentation highlighting its fully integrated biopharmaceutical platform focused on fibrosis, inflammatory diseases, cancer and pain, following the recent acquisition of Cullgen.
The company’s first product, ETUARY™ (pirfenidone), is described as a market leader in organ fibrosis in China, with new line-extension programs in radiation-induced lung injury and pneumoconiosis supported by encouraging preclinical and phase 2 data.
Lead liver-fibrosis candidate F351 (hydronidone) showed ≥1-stage fibrosis regression at Week 52 in 52.85% of patients versus 29.84% on placebo (p=0.0002) in a China phase 3 trial of CHB‑associated liver fibrosis; an NDA was accepted by the China NMPA in May 2026, and a U.S. IND for MASH has been filed. The deck also outlines a broad targeted protein degrader and degrader‑antibody conjugate pipeline, including CDK2/Cyclin E and TYK2/JAK1 degraders and TRK and GSPT1 programs, supported by China-based discovery, development and manufacturing operations and a global workforce of about 740 employees.
GYRE THERAPEUTICS, INC. Chief Operating Officer Weiguo Ye reported option exercises paired with open-market sales of common stock. On May 22 and May 26, he exercised stock options to acquire a total of 7,500 shares of common stock at an exercise price of $0.75 per share and sold 7,500 shares in open-market transactions.
The reported sale prices include $6.0800 per share for 3,500 shares and a weighted average price of $6.1001 per share for 4,000 shares, with individual trades ranging from $6.04 to $6.1051. Following these transactions, Ye’s directly held common stock position is reported at approximately 700,000 shares, indicating the activity mainly reflects option-related liquidity rather than a large change in overall ownership.
GYRE THERAPEUTICS, INC. Chief Operating Officer Ye Weiguo reported option exercises and related share sales. He exercised stock options covering 22,220 shares of common stock at an exercise price of $0.75 per share and sold the same number of shares in open-market transactions.
The common stock sales on May 20 and May 21, 2026 were executed at a weighted average price of $6.15 per share, with actual sale prices ranging from about $6.05 to $6.29 according to the footnotes. After these transactions, Ye directly owns 700,000 shares of GYRE common stock.
GYRE Therapeutics director Zhang Ping reported a cancellation of stock options previously granted by the company. A stock option covering 250,000 shares of common stock with a $10.18 exercise price and a May 27, 2035 expiration was disposed of back to the issuer.
According to the disclosure, the option was canceled by mutual agreement, and the company will provide consideration whose form and amount it will determine, but this consideration will not have economic value. The canceled grant would have begun vesting on May 27, 2026, with monthly vesting over three additional years, and no shares remain from this option after the transaction.
GYRE Therapeutics Chief Operating Officer Ye Weiguo reported a small exercise-and-sell sequence in common stock. On May 18–19, he exercised stock options covering 9,320 shares of common stock at an exercise price of $0.75 per share and sold the same number of shares in open-market transactions at weighted average prices around $6.37 per share, within disclosed price ranges. Following these transactions, he directly holds 700,000 shares of common stock.
GYRE THERAPEUTICS, INC. Chief Operating Officer Weiguo Ye reported a small exercise-and-sell pattern over two days. On May 14 and 15, 2026, he exercised stock options to acquire a total of 28,680 shares of common stock at $0.75 per share and sold the same number of shares in open-market transactions, at weighted average prices of $6.91 and $6.65, respectively, across multiple trades.
After these transactions, Ye directly owns 700,000 shares of common stock. All options involved were fully vested, and the sales were executed across price ranges disclosed through weighted-average pricing footnotes.